Compare Peptides

Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.

Popular comparisons

Ipamorelin

Category 1
Growth Hormone Secretagogue

Sermorelin

Geref, GRF 1-29

Category 1
Growth Hormone Secretagogue
Overview

A selective growth hormone secretagogue that stimulates GH release with minimal effects on cortisol and prolactin. Considered one of the 'cleanest' GH-releasing peptides due to its selectivity.

A synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH). One of the longest-studied GH-releasing peptides with a history of FDA approval for pediatric GH deficiency.

Mechanism of Action

Binds to ghrelin receptors (GHS-R) in the pituitary gland, triggering pulsatile growth hormone release. Unlike other GH secretagogues, it does not significantly increase cortisol, ACTH, or prolactin levels.

Directly stimulates the pituitary gland to produce and release growth hormone through the natural GHRH pathway. Maintains the body's natural feedback mechanisms, reducing the risk of GH excess.

Common Uses
  • Growth hormone optimization
  • Improved sleep quality
  • Fat loss
  • Muscle recovery and growth
  • Anti-aging protocols
  • Growth hormone deficiency treatment
  • Anti-aging protocols
  • Improved sleep
  • Body composition improvement
  • Recovery enhancement
Known Risks
  • Headaches
  • Water retention
  • Tingling sensations
  • Limited long-term human data
  • May affect blood sugar
  • Injection site reactions (redness, swelling)
  • Headaches
  • Flushing
  • Dizziness
  • Generally well-tolerated in clinical studies
Regulatory Status
Category 1

Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.

Category 1

Previously FDA-approved as Geref for diagnostic use and pediatric GH deficiency (withdrawn from market for commercial reasons, not safety). Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.

This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.